AstraZeneca is likely to run an additional global trial to assess the efficacy of its COVID-19 vaccine using a lower dosage, its chief executive said amid questions over the results from its late-stage study.
Instead of adding the trial to an ongoing U.S. process, AstraZeneca might launch a fresh study to evaluate a lower dosage of its vaccine that performed better than a full dosage.
“Now that we’ve found what looks like a better efficacy we have to validate this, so we need to do an additional study,” , Pascal Soriot said.
The news comes as AstraZeneca faces questions about its success rate that some experts say could hinder its chances of getting speedy U.S. and EU regulatory approval.
Meanwhile, UK local lockdown tiers were announced on Thursday, revealing what restrictions Brits will be living under until at least December 16.
London and Liverpool managed to escape Tier 3 rules but there was misery for millions in Manchester and Newcastle who will be plunged into the toughest Covid restrictions next week
Each area will be placed into one of three tiers when lockdown ends on December 2 – but the system has been toughened from the previous regime, meaning more authorities will move into the higher tiers.
Areas which make progress in slowing the spread of the virus could still be moved down a tier before Christmas, however, with the first review of the tiers due to take place by December 16.
Follow our coronavirus live blog below for the very latest news, reaction and updates on the lockdown plans…